| 2022 | Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea | 성주명 | Article |
| 2008 | Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial | 성주명 | Meeting Abstract |
| 2007 | Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (VELCADE (R), thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with VELCADE for newly diagnosed multiple myeloma: Interim results of phase II trial | 성주명 | Meeting Abstract |
| 2012 | Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: Results of a phase II trial | 성주명 | Article |
| 2005 | Signaling mechanisms of anti-proliferation by sphingosine 1-phoshate (S1P) on acute promyelocytic leukaemia cell lines | 성주명; 문영철 | Meeting Abstract |
| 2013 | Single nucleotide polymorphism array-based karyotyping in acute myeloid leukemia or myelodysplastic syndrome with trisomy 8 as the sole chromosomal abnormality | 정화순; 성주명; 허정원; 문영철 | Article |
| 2011 | Single nucleotide polymorphism array-based karyotyping shows sequential genomic changes from monosomy to copy-neutral loss of heterozygosity of chromosome 7 and 20q deletion within a balanced translocation t(14;20) in AML | 정화순; 성주명; 허정원; 문영철 | Article |
| 2015 | Submicroscopic Deletions of Immunoglobulin Heavy Chain Gene (IGH) in Precursor B Lymphoblastic Leukemia with IGH Rearrangements | 정화순; 성주명; 유은선; 허정원; 문영철 | Article |
| 2006 | The intention to treat analysis of the different post remission therapy modalities in AML patients with the "Intermediate Risk Group (IPG)" based on cytogenetics. | 성주명; 문영철 | Meeting Abstract |
| 2009 | The Level of Peroxiredoxin and Catalase On Single Cell Level Is Correlated with the Positivity of Ph Chromosome in the Bone Marrow of CML Patients During Imatinib Therapy. | 성주명; 이서구; 유은선; 허정원; 이경은; 문영철; 남은미; 우현애 | Meeting Abstract |
| 2006 | The LTB4 receptor is involved not only in the downstream pathway of rhG-CSF mobilization but in the LTB4 mobitization pathway in C57BL/6 mice. | 이순남; 성주명; 유은선; 이경은; 문영철 | Meeting Abstract |
| 2014 | Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer | 이순남; 성순희; 성주명; 이경은; 문영철; 남은미 | Article |
| 2003 | Transepithelial migration of neutrophils in response to leukotriene B4 is mediated by a reactive oxygen species-extracellular signal-regulated kinase-linked cascade | 성주명; 문영철 | Article |
| 2010 | Unsorted human adipose tissue-derived stem cells promote angiogenesis and myogenesis in murine ischemic hindlimb model | 성주명; 권기환 | Article |
| 2017 | VARIABLE NATURAL KILLER CELL ACTIVITY IN HEMATOLOGIC MALIGNANCIES AT DIAGNOSIS | 성주명; 허정원; 문영철 | Meeting Abstract |
| 2010 | Variant Philadelphia chromosome identified by interphase fluorescence in situ hybridization (FISH) without evidence on G-banded karyotyping and metaphase FISH | 정화순; 성주명; 허정원; 문영철 | Article |
| 2011 | Various patterns of IgH deletion identified by FISH using combined IgH and IgH/CCND1 probes in multiple myeloma and chronic lymphocytic leukemia | 정화순; 성주명; 허정원; 문영철 | Article |
| 2008 | Velcade (R), Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial. | 성주명 | Meeting Abstract |
| 2007 | Velcade (R), thalidomide, dexamethasone (VTD) induction therapy followed by melphalan, prednisone, thalidomide (MPT) maintenance as a first line treatment for the patients (pts) with multiple myeloma (MM) who are non-transplant candidates: Early analysis from the Korean multiple myeloma working party | 성주명 | Meeting Abstract |
